BONUSCAP-ZERTIFIKAT - ELI LILLY & CO | Market Closed - BOERSE MUENCHEN 15:46:14 2024-05-28 EDT | ||
| 998.8 EUR | -1.29% |
|
| Current month | +4.53% | ||
| 1 month | +14.87% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 24-05-28 | 998.8 | -1.29% |
| 24-05-27 | 1,012 | +0.58% |
| 24-05-24 | 1,006 | +0.68% |
| 24-05-23 | 999.2 | +0.31% |
| 24-05-22 | 996.1 | -0.71% |
Real-time BOERSE MUENCHEN
Last update May 28, 2024 at 03:46 pm
More quotesStatic data
| Product type | Bonus- und Teilschutz-Zertifikate |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
UniCredit
|
| WKN | HD3TAJ |
| ISIN | DE000HD3TAJ2 |
| Date issued | 2024-03-18 |
| Strike | 1,300 $ |
| Maturity | 2025-06-20 (388 Days) |
| Parity | 1 : 1 |
| Emission price | 897.2 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1,015 € |
|---|---|
| Lowest since issue | 831 € |
| Spread | 0.12 € |
| Spread % | 0.01% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
807.9
USD
Average target price
850.8
USD
Spread / Average Target
+5.31%
- Stock Market
- Certificates
- Certificat
